Delivering pharmaceuticals across the skin to treat disease is very challenging. The skin’s role is to protect the body from a range of chemical and environmental assaults, so bypassing this active system requires a new and innovative approach.
Botanix has licensed a novel transdermal drug delivery technology known as Permetrex™ which is designed to deliver pharmaceuticals through the skin more effectively and is differentiated from other approaches in that:
- it does not utilize chemicals which have a tendency to dry the skin and are therefore not desirable for diseases such as acne, psoriasis and atopic dermatitis;
- it creates substantial kinetic energy when applied to the skin, which facilitates the rapid delivery of active pharmaceutical ingredients across the stratum corneum and into the lower layers of the skin; and
- it can accommodate other chemicals which can selectively leave parts of the formulation on the skin in a protective coating for extended absorption and/or protection of the skin.
The active pharmaceutical ingredient utilized in Botanix’ product candidates has very low oral bioavailability, meaning that very little of the drug is absorbed by the body if taken in tablet, capsule or other oral delivery forms. This leads to inconsistent blood levels of the drug, which in turn reduces efficacy and can potentially cause safety issues.
Transdermal delivery avoids the ‘first-pass’ effect of liver metabolism and potentially enabling lower dosage levels of active pharmaceutical ingredients to be rapidly and reliably absorbed with high bioavailability.
Botanix is actively working with a number of pharmaceutical partners who are using the Permetrex delivery system to formulate their proprietary actives, into new and more effective formulations for clinical development. Botanix welcomes new collaborations and attends many industry conferences each year – look us up.